All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 650+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Despite negative FDA adcomm, there’s still hope for Lykos Therapeutics’ MDMDA-assisted therapy
Small molecule, MDMA, psychedelic, Post-traumatic stress disorder (PTSD) - Read more

Zevra Therapeutics lysosomal disorder med gets 11-5 thumbs up from FDA adcomm
Small molecule, Niemann-Pick disease type C - Read more

THE GOOD
Business Development

Mallinckrodt Pharmaceuticals sells Therakos business to CVC Capital Partners for $925M (purchased in 2015 for $1.33B)
Small molecule, lymphoma, cancer, extracorporeal photopheresis - Read more

THE GOOD
Clinical Trials

Bayer’s heart failure med doesn’t fail in Ph3
Small molecule, heart failure - Read more

Lantern Pharma posts positive Ph2 clinical update in never-smoker lung cancer
Small molecule, lung cancer - Read more

THE GOOD
Company Launches

One new company (TRC 2004) from Two River & Third Rock collab, licences bispecific T-Cell engager from Genor Biopharma
Bispecific antibody, T-cell engager, autoimmune, arthritis - Read more

THE GOOD
Fundraises

MBX Biosciences $63.5M Series C
Peptide therapeutics, endocrine disorder, metabolic disorder, hypoparathyroidism, post-bariatric hypoglycemia - Read more

THE GOOD
Partnerships

Galderma works towards dermatology R&D pact with L’Oréal
Research & development, dermatology, aging - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Approvals & Labels

Actinium Pharmaceuticals’ blood cancer med rejected by FDA, turns to partnerships
Antibody-drug conjugate, radiopharma, leukemia, blood cancer - Read more

THE BAD
Clinical Trials

Nuvation Bio pauses solid tumor asset development after disappointing Ph1 safety and efficacy analysis
Small molecule, solid tumor, cancer - Read more

THE BAD
Company Shutdown

Lacerta Therapeutics shuts down
AAV gene therapy, central nervous system - Read more [Paywall]

THE BAD
Earnings & Finances

BioNTech still suffering from post-COVID revenue withdrawal, posts €808M ($883M) net loss for Q2 2024
mRNA, COVID-19 vaccine - Read more

THE BAD
Layoffs

Bristol Myers Squibb to cut 117 jobs at New Jersey site, as part of overall 6% (2,200 roles) workforce reduction - Read more

Sumitomo Pharma America to lay off 53 staffers at Marlborough site - Read more

Diagnostic/molecular test maker Cepheid to axe 635 Bay Area employees - Read more 

THE BAD
Partnerships

BioNTech opts out of bispecific antibody collab with Genmab
Bispecific antibody, solid tumor, lung cancer - Read more

Bristol Myers Squibb also backs out of bispecific antibody collab, this one with Agenus
Bispecific antibody, colorectal cancer - Read more

THE UGLY
No Ugly News today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.